Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs
Executive Summary
In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.
You may also be interested in...
PK Evaluation In Pregnancy: Can HIV Show A Way Forward?
US FDA workshop on efforts to advance pharmacokinetic data collection in pregnant women highlights the (slow-moving) antiretroviral experience, but COVID therapies show that regulatory receptiveness is a poor match for recruitment and liability concerns.
Boston Bags Assets From GSK and Novartis
The US firm is getting its hands on eight programs from two of the world's leading drug makers, seeing an opportunity in areas such as antibiotics where solutions may be more likely to come from biotech rather than big pharma.
Roivant Splashes Cash Again To License GSK Skin Disorder Drug
The UK drug maker is tightening its R&D focus by selling on the psoriasis and atopic dermatitis investigational drug tapinarof to Dermavant, banking a hefty £150m up front and possibly another £100m after that.